MODULATORS OF COMPLEMENT ACTIVITY
The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.
1 - 46 . (canceled)
47 . A pre-filled syringe comprising a pharmaceutical composition comprising:
a single dose of R5000; and
a pharmaceutically acceptable excipient comprising a salt and a buffering agent.
48 . The pre-filled syringe of claim 47 , wherein the salt comprises sodium chloride.
49 . The pre-filled syringe of claim 48 , wherein the sodium chloride is present at a concentration of from 25 mM to 100 mM.
50 . The pharmaceutical composition of claim 47 , wherein the buffering agent comprises sodium phosphate.
51 . The pre-filled syringe of claim 50 , wherein the sodium phosphate is present at a concentration of from 10 mM to 100 mM.
52 . The pre-filled syringe of claim 47 , wherein the pharmaceutical composition comprises about 50 mM sodium phosphate.
53 . The pre-filled syringe of claim 47 , comprising a pH of from 6.5 to 7.5.
54 . The pre-filled syringe of claim 47 , wherein the R5000 is present at a concentration of from 1 mg/mL to 400 mg/mL.
55 . The pre-filled syringe of claim 53 , wherein the R5000 is present at a concentration of about 40 mg/mL.
56 . The pre-filled syringe of claim 47 , wherein the pharmaceutical composition comprises:
40 mg/mL of R5000;
75.7 mM sodium chloride;
50 mM sodium phosphate; and
a pH of 7.0±0.3.
57 . A kit comprising the pre-filled syringe of claim 47 and instructions for use thereof.
58 . A method of inhibiting hemolysis in a subject in need thereof, the method comprising subcutaneously administering via the pre-filled syringe of claim 47 the pharmaceutical composition to the subject.
59 . A method of inhibiting C5 activity in a subject, the method comprising subcutaneously administering via the pre-filled syringe of claim 47 the pharmaceutical composition to the subject.